Jacobs Engineering Group Inc. (NYSE:JEC) has received an engineering, procurement and construction management (EPCM) contract from Pfizer Inc. for a new gene therapy manufacturing facility located at the company's manufacturing site in Sanford, North Carolina. Under the terms of the contract, Jacobs will perform all required services to design, build and qualify the multi-product facility, which will manufacture gene therapy products upon completion. In addition to EPCM, Jacobs will provide design, expediting and commissioning services for the project.

Gene therapy is an emerging area of medical research focused on highly specialized, one-time, transformative treatments addressing the root cause of diseases caused by genetic mutation.

"As a leader in gene therapy EPCM projects, Jacobs delivers end-to-end solutions in support of gene therapy research and advancement," said Jacobs Life Sciences, Consumer Goods and Manufacturing Senior Vice President and General Manager Ken Gilmartin. "Working on this project, we envision a day in the future when these potentially transformative gene therapies become available to treat medical conditions to help people enjoy healthier lives."

Jacobs leads the global professional services sector delivering solutions for a more connected, sustainable world. With $15 billion in combined revenue and a talent force more than 74,000 strong, Jacobs provides a full spectrum of services including scientific, technical, professional and construction- and program-management for business, industrial, commercial, government and infrastructure sectors. For more information, visit www.jacobs.com.

Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management's current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our Form 10-K for the year ended September 29, 2017, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005133/en/

Copyright Business Wire 2010